- CEO
- Soo Hong
- Full Time Employees
- 88
- Sector
- Commercial services
- Industry
- Miscellaneous commercial services
- Address
- Rockville United States
- IPO Date
- Jul 13, 2020
- Business
- Psomagen, Inc. is a genomics and multi-omics contract research organization that provides comprehensive genetic sequencing, bioinformatics, and clinical diagnostic services to academic institutions, biotechnology and pharmaceutical companies, healthcare organizations, and government research agencies. Founded in 2004 as a United States subsidiary of South Korea-based Macrogen Inc. and formerly known as Macrogen Corp. USA prior to its corporate rebranding and subsequent public listing on the KOSDAQ via Korean Depositary Receipts, the company is headquartered in Rockville, Maryland, and maintains College of American Pathologists (CAP) accredited and Clinical Laboratory Improvement Amendments (CLIA) certified laboratory facilities serving clients across North America and international markets.
The company operates across genomic research, clinical diagnostics, and consumer health segments, delivering a systematic portfolio of laboratory and analytical offerings: Next-Generation Sequencing (NGS) services, including whole genome sequencing (WGS), whole exome sequencing (WES), targeted gene panel sequencing, transcriptomics and RNA sequencing (RNA-seq), epigenomic analysis such as ChIP-seq and Methyl-seq, and metagenomic microbiome sequencing; Capillary Electrophoresis Sequencing (CES) and Sanger sequencing solutions, delivering standard DNA sequencing, fragment analysis, and plasmid sequencing; Single-Cell and Spatial Biology services, encompassing single-cell RNA sequencing, spatial transcriptomics, and high-resolution tissue spatial imaging; Proteomics and Multi-Omics profiling, offering high-throughput protein biomarker discovery and multiplex protein quantification assays; Clinical and Molecular Diagnostic services, comprising hereditary cancer screening, somatic oncology testing, carrier screening, and pharmacogenomics (PGx); Direct-to-Consumer (DTC) and Wellness testing kits, including gut microbiome profiling panels; and Advanced Bioinformatics services, providing tailored computational pipelines, variant annotation, statistical genomics, and secure cloud-hosted data delivery.
In recent developments, Psomagen, Inc. has accelerated its expansion into spatial biology and high-throughput proteomics by deploying advanced analytical platforms, including partnerships and service validations with Olink Proteomics for large-scale protein biomarker discovery and 10x Genomics for single-cell and spatial tissue profiling. The company has diversified its sequencing instrumentation through the operational adoption of next-generation sequencing platforms such as Element Biosciences' AVITI system and Pacific Biosciences long-read sequencing technology, optimizing operational efficiency, assay accuracy, and cost-per-sample economics. Furthermore, Psomagen has strengthened its public-sector and institutional engagement through research service contracts with biomedical organizations, including the National Institutes of Health (NIH), while continuing to upgrade its Rockville facilities with automated sample preparation workflows and expanded commercial offerings in clinical microbiome and multi-omics testing.